Zogenix

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Zogenix sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 8 completed top decile by trial count

Zogenix: 9 sponsored US clinical trials, none currently recruiting.

Zogenix sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 5 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Refractory Seizures, with 1 trials.

Top-decile sponsor footprint

Zogenix ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder

NCT05064878
COMPLETED Phase 3

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

NCT03936777
COMPLETED Phase 1

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

NCT02411526
COMPLETED Phase 1

A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

NCT01592110
COMPLETED Phase 3

Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

NCT01115569
COMPLETED Phase 3

Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

NCT01081912
COMPLETED Phase 4

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

NCT01016834
COMPLETED Phase 2

A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack

NCT00530517
COMPLETED Phase 1

A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System

NCT00614029

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 1
Phase 3 4
Phase 4 1

Therapeutic Areas

Refractory Seizures 1
Epileptic Spasm 1
Generalized Tonic Clonic Seizure 1
CDKL5 Deficiency Disorder 1
Epileptic Encephalopathy 1
Dravet Syndrome 1
Lennox Gastaut Syndrome 1

How the Zogenix archive is shaped

9 indexed studies, none listed as recruiting (0% open); 8 completed (89%).

Phase mix: 5 late (III/IV) vs 4 early (I/II) (balanced across stages).

Top condition: Refractory Seizures (1 trial), 6 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Zogenix: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Zogenix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Zogenix4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Zogenix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Zogenix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Zogenix page

9 registered trials is a research-attention snapshot, not an endorsement of Zogenix or any single study.

  • None of Zogenix's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Refractory Seizures is the condition Zogenix studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Refractory Seizures trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Zogenix pipeline card: 9 registered trials from official public datasets.Report a data error.